Biotherapeutics News and Research

RSS

Neuralstem announces completion of $10 million registered direct offering

Neuralstem, Inc. (NYSE Amex: CUR) announced that it has completed its previously announced registered direct offering of $10 million of units to institutional investors. The units were priced at $2.80 and consisted of: (i) one share of common stock, and (ii) 3/4 common stock purchase warrant. The warrants have an exercise price of $3.25 and a term of three years. Net proceeds from this offering, after deducting placement agent fees and other offering expenses, total approximately $9.2 million. All of the securities were offered pursuant to an effective shelf registration statement.

1 Jul 2010

Oxygen' common stock to begin trading on Swiss SIX Exchange

Oxygen Biotherapeutics, Inc. announced today that the company's common stock will begin trading on the Swiss SIX Exchange with the opening of trading tomorrow, Tuesday, June 29, 2010. The company's shares will trade under the same ticker symbol, OXBT, as they currently do on the NASDAQ Capital Market.

28 Jun 2010

Alnylam presents data on novel delivery lipids at IBC 6th Annual Cell Line Development and Engineering conference

Alnylam Biotherapeutics, a division of Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today the presentation of new data at the IBC 6th Annual Cell Line Development and Engineering conference held in San Francisco, California from June 21 - 24, 2010.

24 Jun 2010

Oxygen Biotherapeutics' common stock approved for secondary listing on SIX Swiss Exchange

Oxygen Biotherapeutics, Inc. announced today that its common stock has been approved for secondary listing on the SIX Swiss Exchange in addition to its listing on the NASDAQ Capital Market. Bank am Bellevue of Zurich is acting as the company's listing agent.

21 Jun 2010

Talecris CEO receives Ernst & Young Entrepreneur Of The Year 2010 Award

Lawrence D. Stern, chairman and CEO of Talecris Biotherapeutics, received the Ernst & Young Entrepreneur Of The Year® 2010 Award in the health sciences category in the Carolinas at a ceremony last night in Charlotte, N.C. The Ernst & Young awards program recognizes entrepreneurs who demonstrate extraordinary success in the areas of innovation, financial performance and personal commitment to their businesses.

19 Jun 2010

Carolinas recipients for 2010 Ernst & Young Entrepreneur Of The Year award announced

Ernst & Young LLP is pleased to announce the winners of the Ernst & Young Entrepreneur Of The Year award in the Carolinas. This group of leading entrepreneurs was selected by an independent judging panel made up of regional business, academic and community leaders. The winners were revealed at a gala event on June 17, 2010 at The Westin Charlotte hotel in Charlotte, North Carolina.

19 Jun 2010

GTC Biotherapeutics closes new $7 million secured convertible debt financing

GTC Biotherapeutics, Inc. announced the closing of a new $7 million secured convertible debt financing by its strategic partner, LFB Biotechnologies SAS, in connection with a restructuring of GTC's operations which will result in a downsizing of approximately 30 full-time positions at its headquarters and an additional 20 positions at its farm facility.

16 Jun 2010

Trubion announces Pfizer's decision to discontinue development of TRU-015 for RA

Trubion Pharmaceuticals, Inc. today announced Pfizer's decision to discontinue development of TRU-015 (PF-05212374), an investigational drug in Phase 2 evaluation for the treatment of rheumatoid arthritis (RA) developed under the companies' CD20 collaboration. However, Pfizer has confirmed that it will continue to develop SBI-087 (PF-05230895), Trubion's next-generation, humanized, subcutaneous CD20 RA product candidate also in Phase 2 clinical evaluation.

15 Jun 2010

Dyadic signs non-binding term sheet with EnGen Bio for potential outlicense of C1 platform technology

Dyadic International, Inc., a leading biotechnology company focused on the development and manufacture of bioproducts based on its cutting-edge C1 technology to address the needs of multi-billion dollar markets for biofuels, biotherapeutics and industrial enzymes, announced today that it has signed a non-binding term sheet with EnGen Bio, Inc. for a potential outlicense, on an exclusive worldwide basis, of Dyadic's C1 platform technology for applications in biopharmaceutical drug development.

10 Jun 2010

NWBT announces release of new detailed report by Pharmaceuticals and Biotech Analyst

Northwest Biotherapeutics, Inc., developer of the DCVax personalized cancer vaccine, today announced the release of a new detailed report by Pharmaceuticals and Biotech Analyst Dr. Navid Malik of the London-based Matrix Group.

9 Jun 2010

Protalix BioTherapeutics reports positive results from PRX-105 Phase I clinical trial

Protalix BioTherapeutics, Inc. announced today the completion of its phase I clinical trial of PRX-105, a plant cell expressed pegylated recombinant human acetylcholinesterase in development for biodefense indications. The trial established the pharmacokinetics of the protein and demonstrated that single dose, intravenous administration of PRX-105 is safe and well tolerated.

8 Jun 2010

Grifols to acquire Talecris Biotherapeutics

Grifols a global healthcare company and leading producer of plasma protein therapies, and Talecris a U.S.-based biotherapeutics products company, today announced that they have signed a definitive agreement through which Grifols will acquire Talecris for a combination of cash and newly-issued Grifols non-voting shares having an aggregate value today of approximately $3.4 billion (euro 2.8 billion), creating a global leader of life-saving and life enhancing plasma protein therapeutics.

7 Jun 2010

Oxycyte perfluorocarbon emulsion demonstrates marked neuroprotective effect in rat model of spinal cord injury

Oxygen Biotherapeutics, Inc. today reported on the results of two University of Miami Miller School of Medicine studies involving the Company's third-generation perfluorocarbon, Oxycyte® perfluorocarbon emulsion. Both study reports showed that Oxycyte® has a marked neuroprotective effect in a rat model of spinal cord injury.

4 Jun 2010

Research finding may offer future alternative to antibiotics

A team of scientists from government, academia and private industry has developed a novel treatment that protects mice from infection with the bacterium that causes tularemia, a highly infectious disease of rodents, sometimes transmitted to people, and also known as rabbit fever. In additional experiments with human immune cells, the treatment also demonstrated protection against three other types of disease-causing bacteria that, like the tularemia bacteria, occur naturally, can be highly virulent, and are considered possible agents of bioterrorism.

28 May 2010

Positive results from Phase 1 study evaluating IV administration of JX-594 to metastatic cancer patients

Jennerex, Inc., a clinical-stage cancer biotherapeutics company, today reported positive results from its Phase 1 dose escalation study evaluating the intravenous administration of JX-594 to patients with metastatic cancer. The data presented today demonstrated clear dose-related delivery to solid tumors, cancer-targeted replication and gene expression, and anti-cancer effects of JX-594 delivered IV.

21 May 2010

Caliper to sell RapidTrace solid phase extraction and TurboVap evaporation product lines to Biotage for $16.5M

Caliper Life Sciences, Inc., a leading provider of tools and services for drug discovery and life sciences research, today announced that it reached an agreement to sell its RapidTrace® solid phase extraction and TurboVap® evaporation product lines to Biotage AB for $16.5 million in cash.

18 May 2010

BaroFold licenses PreEMT Technology to Nuron Biotech for development of BaroFeron

BaroFold, Inc. today announced that it has entered into an agreement to exclusively license its PreEMT™ Technology to Nuron Biotech for the development of BaroFeron™ and follow-on interferon beta products. BaroFeron is a proprietary recombinant human interferon beta being developed for the treatment of multiple sclerosis. Specific terms of the agreement are not disclosed.

17 May 2010

NASDAQ Biotechnology Index semi-annual re-ranking to become effective May 24, 2010

The NASDAQ OMX Group, Inc. announced today the results of the semi-annual re-ranking of the NASDAQ Biotechnology Index®, which will become effective prior to market open on Monday, May 24, 2010.

15 May 2010

Novel vaccines for deadly diseases to be presented at AAPS' NBC

Novel vaccines for diseases ranging from the flu to HIV highlight a week's worth of biotechnology research at the American Association of Pharmaceutical Scientists' National Biotechnology Conference. Scientists from academia, industry, and government will gather at the Hilton San Francisco Union Square Sunday, May 16 -Thursday, May 20 to share research and advances in biotherapeutics.

14 May 2010

Jennerex to present key data on JX-594 Phase 1 dose escalation clinical study at ASGCT Annual Meeting

Jennerex, Inc., a clinical-stage cancer biotherapeutics company, today announced that key data from its JX-594 intravenous administration Phase 1 dose escalation clinical study will be presented at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting taking place May 19-22, 2010, in Washington DC.